Knight Therapeutics Inc. Announces Board Change
MONTREAL, CANADA–(Marketwired – Jan 21, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight’s Board of Directors. “Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date,” said Jonathan Ross […]
Knight Therapeutics Inc. and NeurAxon Inc. Form Partnership for the Commercialization of NeurAxon’s Innovative Products
MONTREAL, QUEBEC–(Marketwired – Jan 1, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with NeurAxon Inc. (“NeurAxon”) for the commercialization of NeurAxon’s innovative products in various stages of development (“Pharmaceuticals”) in Canada, Israel, South Africa and Russia […]
Knight Therapeutics Completes Previously Announced “Bought Deal” of Common Shares for $87 Million
MONTREAL, QUEBEC–(Marketwired – Dec. 22, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX:GUD) today announced that it has completed its previously announced bought deal offering (the […]
Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy
MONTREAL, QUEBEC–(Marketwired – Dec. 16, 2014) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly owned subsidiaries (“Knight”), announced today that it has committed to invest US$25 million into Domain Partners IX, L.P. (“Domain Fund”) and US$10 million in Sanderling Ventures VII, L.P. (“Sanderling Fund”). These investments into proven successful life science funds complement […]
Knight Therapeutics Announces Increase of Previously Announced “Bought Deal” of Common Shares to $87 Million
MONTREAL, QUEBEC–(Marketwired – Dec. 4, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX:GUD) is pleased to announce that it has amended the terms of its previously […]
Knight Therapeutics Enters into Agreement for a $75 Million Bought Deal of Common Shares
MONTREAL, QUEBEC–(Marketwired – Dec. 3, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX:GUD) today announced that it has entered into a bought deal agreement with a […]
Knight Therapeutics Inc. and CRH Medical Corporation Sign Secured Debt Financing Agreement
MONTREAL, CANADA–(Marketwired – Dec. 2, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a senior secured debt agreement with CRH Medical Corporation (TSX:CRH)(OTCQX:CRMMF) (“CRH”), a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal […]
Knight Sells Priority Review Voucher to Gilead
MONTREAL, QUEBEC–(Marketwired – Nov. 19, 2014) – Knight Therapeutics Inc., (TSX:GUD) through one of its wholly owned subsidiaries (“Knight”), today announced the sale of its Neglected Tropical Disease Priority Review Voucher (“PRV”). The PRV was granted to Knight in March of this year with the approval of Impavido® (miltefosine) for treatment of patients with visceral, […]
Knight Reports Third Quarter 2014 Results
MONTREAL, CANADA–(Marketwired – Nov. 12, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) today reported its financial results for the quarter ended September 30, 2014. Third Quarter 2014 Highlights On July 3, 2014, Knight entered into a secured debt agreement whereby it issued a secured loan of $6.9 million [US$6.5 million] to Apicore Inc. and Apigen […]
Notice of Knight Therapeutics' Third Quarter 2014 Results Conference Call
MONTREAL, CANADA–(Marketwired – Nov. 6, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2014 financial results on Wednesday, November 12, 2014 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST) hosted by Jonathan Goodman, President and […]
